Litcius/Paper detail

Adjuvant 131I-metuximab for hepatocellular carcinoma after liver resection: a randomised, controlled, multicentre, open-label, phase 2 trial

Jun Li, Jingliang Xing, Yefa Yang, Jingfeng Liu, Wentao Wang, Yong Xia, Zhenlin Yan, Kui Wang, Dong Wu, Lu Wu, Xuying Wan, Tian Yang, Chunfang Gao, Anfeng Si, Hongyang Wang, Mengchao Wu, Wan Yee Lau, Zhi‐Nan Chen, Feng Shen

2020˜The œLancet. Gastroenterology & hepatology69 citationsDOI

Topics & Concepts

MedicineHepatocellular carcinomaAdjuvantInternal medicinePopulationHepatectomyIntention-to-treat analysisGastroenterologyRandomized controlled trialSurgeryResectionEnvironmental healthHepatocellular Carcinoma Treatment and PrognosisAmoebic Infections and TreatmentsCancer, Hypoxia, and Metabolism
Adjuvant 131I-metuximab for hepatocellular carcinoma after liver resection: a randomised, controlled, multicentre, open-label, phase 2 trial | Litcius